Savara (SVRA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SVRA Savara

Watchlist

3.070
-0.010-0.32%

Close Dec 31 16:00 ET

3.070
0.0000.00%

Post 17:05 ET

526.87MMarket Cap-7.14P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Savara Inc. (NASDAQ:SVRA) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company
Yahoo FinanceDec 29, 2024 09:54 ET
Wells Fargo Initiates Savara(SVRA.US) With Buy Rating, Announces Target Price $8
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
Wells Fargo Initiates Coverage On Savara With Overweight Rating, Announces Price Target of $8
BenzingaDec 20, 2024 08:24 ET · Ratings
Savara Analyst Ratings
BenzingaDec 19, 2024 10:18 ET · Ratings
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsDec 19, 2024 05:31 ET · Ratings
Savara Positioned for Success: Buy Rating Boosted by Strong BLA Progress and Market Potential for Molbreevi
TipRanksDec 19, 2024 05:25 ET · Ratings

Comments

Trytosaveabit

Dec 18, 2024 15:09

Update

$Savara (SVRA.US)$ Reuters· just
Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Jaguar8

Dec 1, 2024 01:14

🔵Watchlist Monday December 2. NFA. Trade the Chart. No emotions. No FOMO

NOTE:
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
4. If you are expecting all stocks to be a runner,then you are set for failure, losses, and bagholding. Not all good news run and not all bad news crash the pri...

Trytosaveabit

Nov 22, 2024 07:08

Watching

$Savara (SVRA.US)$ Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...

Jaguar8

Nov 22, 2024 07:07

NEWS

$Savara (SVRA.US)$
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trialresults for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meet...

Teddy123

Nov 12, 2024 07:26

In the pipeline

$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...

Heat List

Overall

No Data